A national study on conditional survival and excess mortality after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

8598 Background: The aim of this study was to investigate conditional survival and standardized mortality ratios (SMR) after high-dose therapy with autologous stem-cell transplantation (HDT) for non-Hodgkin lymphoma (NHL) in a national population-based cohort, and to analyse cause of death and incidence of second malignancies. Methods: All patients ≥ 18 years treated with HDT for NHL in Norway 1987-2008 were included (n =578). Information about cause of death from Statistics Norway and second malignancies from Cancer Registry of Norway were linked with clinical data. Treatment related mortality (TRM) was defined as death from a complication to HDT in tumour free patients. Observation time was estimated from HDT to death or cut-off at June 30th 2014 (median 6.7 years, range 0-27). Data on second cancer was available until end of 2012. Results: The 10- and 15-year overall survival (OS) was 52% (95%CI 48%-56%) and 49% (95%CI 44%-53%). Conditional 5-year OS are shown in the table. SMR was 12.3 (95% CI 11.0-13...